{{Rsnum
|rsid=9623117
|Gene=TNRC6B
|Chromosome=22
|position=40056115
|Orientation=plus
|GMAF=0.3058
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=TNRC6B
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 3.5 | 37.2 | 59.3
| HCB | 0.7 | 6.6 | 92.7
| JPT | 0.0 | 4.4 | 95.6
| YRI | 83.0 | 16.3 | 0.7
| ASW | 38.6 | 49.1 | 12.3
| CHB | 0.7 | 6.6 | 92.7
| CHD | 0.0 | 3.7 | 96.3
| GIH | 8.9 | 54.5 | 36.6
| LWK | 85.5 | 13.6 | 0.9
| MEX | 0.0 | 27.6 | 72.4
| MKK | 55.8 | 39.7 | 4.5
| TSI | 6.9 | 34.3 | 58.8
| HapMapRevision=28
}}{{PMID|19117981|OA=1
}} In seven different populations studied, [[rs9623117]](C) was consistently higher in aggressive [[prostate cancer]] cases than in controls (p = 5.0 x 10e-7). The odds ratio (OR) of allele C for aggressive prostate cancer was estimated to be 1.18 (CI: 1.11-1.26). This SNP was also associated with increased risk for nonaggressive prostate cancer, with an odds ratio of 1.11 (CI: 1.04 - 1.19, p = 0.004).

{{PharmGKB
|RSID=rs9623117
|Name_s=
|Gene_s=TNRC6B
|Feature=
|Evidence=PubMed ID:19117981; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Sequence variants at 22q13 are associated with prostate cancer risk. (Initial Sample Size: 1,235 aggressive cases, 1,599 controls; Replication Sample Size: 3,629 aggressive cases, 4,255 non-aggressive cases, 5,738 controls); (Region: 22q13.1; Reported Gene(s): TNRC6B; Risk Allele: rs9623117-C); (p-value= 0.0000005).This variant is associated with Prostate cancer.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740096
}}

{{PMID Auto
|PMID=19434657
|Title=Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
|OA=1
}}

{{PMID Auto
|PMID=19549807
|Title=Prostate cancer risk associated loci in African Americans.
|OA=1
}}

{{PMID Auto
|PMID=20690139
|Title=Meta-analysis of genome-wide and replication association studies on prostate cancer.
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9623117
|overall_frequency_n=52
|overall_frequency_d=128
|overall_frequency=0.40625
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=48
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}